ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Now Available: Top 10 Stocks for 2010

These powerful long-term stocks for 2010 have just been announced. Our top picks for 2009 generated a +34.1% return. Don’t miss out. Learn more now.

Quote:

Search for Ticker

Free Membership

Search:

LCI: Lannett Co Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

LANNETT CO INC (AMEX)
LCI	4.51	-0.04	(-0.88%)	Vol. 2,300	09:49 ET

Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.

General Information

LANNETT INC

9000 State Road Philadelphia, PA 19136 Phone: 215 333-9000 Fax: 215 333-9004 Web: www.lannett.com Email: investors@lannett.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	June
Last Reported Quarter	12/31/09
Next EPS Date	05/11/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	4.55
52 Week High	9.74
52 Week Low	4.10
Beta	0.67
20 Day Moving Average	21,023.50
Target Price Consensus	8.5

% Price Change
4 Week	-23.79
12 Week	-23.27
YTD	-23.01

% Price Change Relative to S&P 500
4 Week	-19.11
12 Week	-20.42
YTD	-10.45

Share Information
Shares Outstanding (millions)	24.85
Market Capitalization (millions)	113.06
Short Ratio	17.97
Last Split Date	03/03/2003

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.10
Current Year EPS Consensus Estimate	0.40
Estimated Long-Term EPS Growth Rate	37.00
Next EPS Report Date	05/11/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	0.00

Fundamental Ratios

P/E
Current FY Estimate:	17.50
Trailing 12 Months:	17.50
PEG Ratio	0.47

EPS Growth
vs. Previous Year	-100.00%
vs. Previous Quarter	-100.00%

Sales Growth
vs. Previous Year	-1.73%
vs. Previous Quarter:	-8.65%

Price Ratios
Price/Book	1.37
Price/Cash Flow	9.60
Price / Sales	0.91

ROE
12/31/09	-
09/30/09	10.65
06/30/09	8.81

ROA
12/31/09	-
09/30/09	6.83
06/30/09	5.57

Current Ratio
12/31/09	-
09/30/09	2.21
06/30/09	2.00

Quick Ratio
12/31/09	-
09/30/09	1.72
06/30/09	1.58

Operating Margin
12/31/09	-
09/30/09	6.54
06/30/09	5.49

Net Margin
12/31/09	-
09/30/09	10.56
06/30/09	8.96

Pre-Tax Margin
12/31/09	-
09/30/09	10.56
06/30/09	8.96

Book Value
12/31/09	-
09/30/09	3.31
06/30/09	3.16

Inventory Turnover
12/31/09	-
09/30/09	4.88
06/30/09	5.13

Debt-to-Equity
12/31/09	-
09/30/09	0.09
06/30/09	0.10

Debt to Capital
12/31/09	-
09/30/09	8.63
06/30/09	9.13


About Zacks \| Advertise \| Affiliate \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2010 Zacks Investment Research